Fox Business - The Power to Prosper
Search Site

Ranbaxy Laboratories

India's Sun Pharma expects Ranbaxy business to be profitable in short term

India's Sun Pharmaceutical Industries Ltd Managing Director Dilip Shanghvi said he expects Ranbaxy Laboratories Ltd to become profitable in the short term.Sun said it will buy Ranbaxy in a $3.2 billion all-share deal, creating the world's fifth-largest generic drug maker from two firms struggling with quality issues in the lucrative United States market.Sun plans to focus on remediation of compliance issues that have resulted in bans at multiple Ranbaxy plants, Shanghvi told analysts on a conference call.Ranbaxy's underlying business has "robust growth," and profitability potential, based on which the price Sun is paying for the deal is "justified," Shanghvi said.The managing director also said Sun would continue to look for acquisition opportunities even after the Ranbaxy acquisition.(This version of the story corrects the first and last paragraphs to say Dilip Shanghvi is managing director, not chairman of Sun Pharma.)(Reporting by Zeba Siddiqui; Editing by Anupama Dwivedi)...

Read More

  1. Novartis Boosted by Drug Launches

    Swiss drug maker Novartis AG (NOVN.VX) Wednesday posted a rise in first-quarter net profit, as new product launches and strength in emerging markets helped offset de...

  2. Ranbaxy Resumes Generic Lipitor Production for U.S.

    Ranbaxy Laboratories Ltd. (500359.BY) said Friday it has resumed manufacturing generic copies of the cholesterol-lowering drug Lipitor for the U.S. market, following...

  3. Ranbaxy Had Smaller Recall of Generic Lipitor in August Over Pill Mix-up

    Ranbaxy Laboratories Ltd. (500359.BY) recalled more than 32,000 bottles of its generic version of cholesterol-lowering drug Lipitor over a potential pill mix-up in A...

  4. Malaysia Unveils MYR5.61 Billion of Investments Via 7 New Projects

    Malaysia Thursday announced seven new projects worth a total of 5.61 billion ringgit ($1.82 billion) ranging from a liquefied natural gas terminal to a drug manufact...

  5. Malaysia PM: Attracted 7 New Projects Worth MYR5.61 Billion

    Malaysia announced Thursday a slew of new projects worth a total of 5.61 billion Malaysian ringgit ($1.82 billion) in investments, as part of its broader ambition to...

  6. Pfizer Sued for Conspiring to Delay Generic Lipitor

    Pfizer (NYSE:PFE) has been sued by five big retailers for allegedly conspiring to delay sales of generic versions of blockbuster drug Lipitor.The drug maker lost pat...

  7. Dr Reddy's Jan-March Net Grows 2.7%; Misses View On One-Time Charge

    Dr. Reddy's Laboratories Ltd. (500124.BY) Friday disappointed investors with a slim 2.7% rise in its fourth-quarter net profit, but this was due mainly to a one-time...

  8. Teva 1Q Profit Up 13% On Branded, Generic Drug Sales

    Teva Pharmaceutical Industries Ltd. (TEVA) said Wednesday its first-quarter profit rose 13%, as sales growth for branded and generic drugs in the U.S. and emerging m...

  9. Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales

    Pfizer Inc.'s (PFE) first-quarter profit declined 19% as sales of its top product, the cholesterol-lowering drug Lipitor, tumbled 71% in the U.S. due to competition ...

  10. UPDATE: Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales

    ("UPDATE: Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales," published at 9:01 a.m. EDT, incorrectly stated sales for Prevnar 13 in the eleventh paragraph. A c...

  11. Ranbaxy Starts Selling Generic Atorvastatin In Australia

    India's Ranbaxy Laboratories Ltd. (500359.BY) Tuesday said it has become the first generic drug maker to started selling generic cholesterol drug atorvastatin in Aus...

  12. Watson Pharma 4Q Profit Surges On Generic Lipitor, Concerta

    Watson Pharmaceuticals Inc.'s (WPI) fourth-quarter profit surged as the introduction of a generic version of Pfizer Inc.'s (PFE) cholesterol drug Lipitor and other p...

  1. FDA bans imports from Sun Pharma plant in India crackdown

    The U.S. Food and Drug Administration (FDA) has banned imports from Indian generic drugmaker Sun Pharmaceutical Industries Ltd's plant at Karkhadi in the western sta...

  2. Japan Stocks Inch Up, But Telecoms Weaken

    Japanese stocks struggled to hold onto their opening gains early Tuesday, with the Nikkei Stock Average up 0.1% to 14,413.08 after dipping into negative territory, w...

  3. EU Regulators to Fine Big Drug Firms

    EU antitrust regulators will fine Denmark's Lundbeck, Germany's Merck KGaA and seven other drugmakers this month for blocking the entry of cheaper generic medicines ...

  4. U.S. Slaps Ban on Another Indian Drugmaker

    The U.S. Food and Drug Administration slapped an import ban on Indian drugmaker Wockhardt Ltd. (532300.BY) after one of the company's plants failed an FDA safety ins...

  5. Ranbaxy to Pay $500 Million in Adulterated Drugs Case

    Indian generic pharmaceutical maker Ranbaxy Laboratories Ltd.'s (500359.BY) U.S. subsidiary has pled guilty to felony charges relating to adulterated drugs made at t...

  6. Ranbaxy to Pay $500 Million in Adulterated Drugs Case; Largest Such Settlement Ever

    Indian generic pharmaceutical maker Ranbaxy Laboratories Ltd.'s (500359.BY) U.S. subsidiary has pled guilty to felony charges relating to adulterated drugs made at t...

  7. Astellas, Daiichi Sankyo See New Drugs Propelling Growth

    Japan's second and third largest drug makers on Monday predicted growth in the current fiscal year as they battle to offset large-scale revenue fallout from patent e...

‹ Prev12Next ›
Freebase CC-BY
Source: Ranbaxy Laboratories on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL